Oncobiologics is a complex biosimilar company focused on developing technically challenging biosimilars in a cost effective way. The first wave of Phase 3 ready products include ONS-3010 (Humira® Biosimilar) and ONS-1045 (Avastin® Biosimilar).
oncobiologics.com
oncobiologics.com
Employees: 51-200
Total raised: $81M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | Perceptive... | perceptive... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 23.12.2015 | - | $50M | - |
| 27.07.2015 | - | $31M | - |
Mentions in press and media 12
| Date | Title | Description |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 23.12.2015 | Oncobiologics raising $50M for Avastin, Humira biosimilars | Oncobiologics has six more biosimilars in preclinical study, the company says. Promoted Telemedicine’s potential to provide healthcare to the world’s most vulnerable Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual... |
| 29.09.2015 | Oncobiologics Raises Equity Funding | Oncobiologics, Inc., a Cranbury, New Jersey-based clinical-stage biopharmaceutical company, closed an additional round of equity financing. Sabby Management, LLC, joined existing institutional investors Perceptive Advisors, Cormorant Global... |
| 28.07.2015 | Oncobiologics Receives $31M | CRANBURY, NJ, Oncobiologics, announced the closing of a $31 million financing. >> Click here for more funding data on Oncobiologics >> To export Oncobiologics funding data to PDF and Excel, click here Proceeds will be use... |
| 27.07.2015 | Daily funding roundup - July 27, 2015 | Palantir received $450M; DraftKings added $300M; Secret Escapes bagged $60M Buyatab Online Inc., a Vancouver, BC, Canada-based international provider of digital gift card solutions, completed a funding round of undisclosed amount. Backers w... |
| 27.07.2015 | Oncobiologics Closes $31M Financing | Oncobiologics, Inc., a Cranbury, NJ-based biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics, closed a $31m financing. The round was led by new investor Perceptive Advisors with p... |
| 27.07.2015 | Oncobiologics raises $31M to develop biosimilars as Humira, Avastin approach patent expiry | Humira is the first drug for which Oncobiologics is developing a biosimilar; it’s entering phase 3 trials at the moment and will be ready to hit the market right as Humira’s patent expires in 2017. Its second will be a biosimilar that mirro... |
| 26.07.2015 | Oncobiologics raises $31M for a PhIII biosimilar play against Humira | Oncobiologics CEO Pankaj Mohan Four years ago, Pankaj Mohan set out to build an independent biosimilars developer, confident that by the time he was ready for a Phase III study of a lead knockoff, the FDA would have completed building the r... |
| 14.10.2011 | NJ biotherapeutics co licensing and research deals worth $80 million | At its official opening, Oncobiologics also announced a strategic partnership with Fox Chase Cancer Center to co-develop a next generation bi-specific antibody cancer platform with enhanced therapeutic capabilities against solid tumors to h... |
| - | NJ biotherapeutics co licensing and research deals worth $80 million | Oncobiologics, a New Jersey-based biotherapeutics company which had its ceremonial opening Friday, announced two deals that are valued by the company at nearly $80 million. The agreements include a licensing deal with early-stage biotechnol... |
Show more